Skip to main content
BCRX
NASDAQ Life Sciences

$70M Upfront Payment Secured by BioCryst in European Navenibart Licensing Deal

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9.28
Mkt Cap
$2.335B
52W Low
$6
52W High
$11.31
52W Position info
55% above low
Off High info
18% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

BCRX sits 55% above its 52-week low of $6.

Summary

BioCryst Pharmaceuticals has entered a European licensing agreement with an Irish affiliate of Neopharmed Gentili for its investigational hereditary angioedema (HAE) drug, navenibart. The deal includes a significant $70 million upfront payment to BioCryst, with potential for up to $275 million in future regulatory and sales milestones, plus tiered royalties of 18% to 30% on net sales. This agreement, which follows an 8-K filing confirming the transaction, strengthens BioCryst's financial position and leverages an existing partnership, allowing the company to optimize its commercial focus while retaining substantial upside from a key pipeline asset. This is a material positive development, providing capital and a clear path for European commercialization of navenibart, which is currently in Phase 3 with a US regulatory filing targeted by the end of 2027.

At the time of this announcement, BCRX was trading at $9.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $6.00 to $11.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BCRX - Latest Insights

BCRX
Nov 04, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.24
Real-time Price: $7.36 info
Change: -$0.880 (-11%) info
Market Cap: $1.878B info
BCRX
Nov 04, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.66
Real-time Price: $7.36 info
Change: -$1.30 (-15%) info
Market Cap: $1.878B info
BCRX
Nov 04, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $8.52
Real-time Price: $7.36 info
Change: -$1.16 (-14%) info
Market Cap: $1.878B info
BCRX
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $7.36 info
Change: -$0.6585 (-8%) info
Market Cap: $1.878B info
BCRX
Aug 25, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.65
Real-time Price: $7.36 info
Change: -$2.29 (-24%) info
Market Cap: $1.878B info